287 related articles for article (PubMed ID: 28589082)
1. Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.
Haddad D
Front Oncol; 2017; 7():96. PubMed ID: 28589082
[TBL] [Abstract][Full Text] [Related]
2. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
3. Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.
Sampath P; Thorne SH
Oncolytic Virother; 2014; 3():1-9. PubMed ID: 27512659
[TBL] [Abstract][Full Text] [Related]
4. Design and testing of novel oncolytic vaccinia strains.
Thorne SH
Methods Mol Biol; 2009; 542():635-47. PubMed ID: 19565925
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
6. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer.
Jefferson A; Cadet VE; Hielscher A
Crit Rev Oncol Hematol; 2015 Sep; 95(3):407-16. PubMed ID: 25900073
[TBL] [Abstract][Full Text] [Related]
7. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?
Thorne SH; Bartlett DL; Kirn DH
Curr Gene Ther; 2005 Aug; 5(4):429-43. PubMed ID: 16101516
[TBL] [Abstract][Full Text] [Related]
8. Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB; Zhao L; Zhang L; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges.
Chaurasiya S; Fong Y; Warner SG
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604787
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects.
Hu H; Xia Q; Hu J; Wang S
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498574
[TBL] [Abstract][Full Text] [Related]
11. Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.
Breitbach CJ; Parato K; Burke J; Hwang TH; Bell JC; Kirn DH
Curr Opin Virol; 2015 Aug; 13():49-54. PubMed ID: 25900822
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
13. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
14. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
16. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
17. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
Yoo SY; Bang SY; Jeong SN; Kang DH; Heo J
Oncotarget; 2016 Mar; 7(13):16479-89. PubMed ID: 26918725
[TBL] [Abstract][Full Text] [Related]
18. Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.
Ricordel M; Foloppe J; Antoine D; Findeli A; Kempf J; Cordier P; Gerbaud A; Grellier B; Lusky M; Quemeneur E; Erbs P
Cancers (Basel); 2018 Jul; 10(7):. PubMed ID: 29996551
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic-dependent expression of early transcription factor subunits leads to stringent control of vaccinia virus replication.
Hagen CJ; Titong A; Sarnoski EA; Verardi PH
Virus Res; 2014 Mar; 181():43-52. PubMed ID: 24394294
[TBL] [Abstract][Full Text] [Related]
20. Employing tumor hypoxia for oncolytic therapy in breast cancer.
Chun YS; Adusumilli PS; Fong Y
J Mammary Gland Biol Neoplasia; 2005 Oct; 10(4):311-8. PubMed ID: 16826462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
